Juvenile rheumatoid arthritis (JRA) is a disorder that causes chronic inflammation of the joints in children less than 16 years of age. The cause of JRA is unknown, however it seems to be related to certain genes that disrupt the immune system, leading to inflammation (especially arthritis). Arthritis is defined as swelling or limitation of motion of the joint accompanied by heat, pain, and/or tenderness. JRA is classified into 7 basic types depending on the number and location of joints involved and the involvement of other body parts. The treatment of JRA in children involves limiting pain and the development of long-term damage. The first treatment for most children with JRA includes non-steroidal anti-inflammatory medicines (NSAID's) such as ibuprofen. Some children require treatment with corticosteroids or other medications that regulate or suppress the immune system. Most children with JRA have symptoms that are well-controlled with medications and have limited disability.
Juvenile rheumatoid arthritis (JRA) is a disorder that causes inflammation of the joints that lasts more than 6 weeks. While children and adults of all ages can develop arthritis, the term "JRA" is reserved for children that develop symptoms before 16 years of age. Some children may have involvement of one joint (i.e., the knee) while others may have inflammation in several joints. In some cases, JRA may lead to poor growth, eye inflammation and bone mineral loss.
The exact cause of JRA is unknown. There seem to be several genes that make a child more likely to get JRA. It is possible that a child with abnormal "JRA genes" may develop JRA after an infection or other environmental trigger.
Up to 100,000 children in the United States have JRA. Symptoms must begin before 16 years of age to be considered JRA.
Sometimes present...
There is no specific JRA test. Your history and physical exam are key for the diagnosis.
Different patients respond differently to different medications. Some options include...
A healthy diet with adequate calcium and vitamin D to minimize bone mineral loss.
Folate is given when methotrexate is used.
Physical therapy is often required to maintain good joint function and range of motion.
The future course of JRA depends on the type of JRA. Many children with JRA will outgrow the disease. Some forms of JRA persist into adulthood and some forms of JRA will be life-long.
Last Updated (Wednesday, 19 May 2010 13:17)